Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites.

Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites. Abstract Text:

Wu-Nan Wu,Linda A McKown,Allen B Reitz,Wu-Nan Wu,Linda A McKown,Allen B Reitz,

The in vivo metabolism of the antipsychotic agent mazapertine was studied after oral administration of mazapertine succinate (40 mg/subject) to two healthy volunteers, and urine (0-24 hours) was obtained for metabolite identification using API-ionspray LC/MS and MS/MS analysis. Unchanged mazapertine (12% of the sample) plus 10 metabolites were profiled, quantified, and tentatively identified on the basis of MS data, Glusulase-hydrolysis, and by comparison to synthetic samples. The formation of mazapertine metabolites are via seven metabolic pathways: (1) phenylhydroxylation, (2) piperidyl oxidation, (3) O-dealkylation, (4) N-dephenylation, (5) oxidative N-debenzylation, (6). depiperidylation, and (7) glucuronidation. Pathways 1, 2, 5 and 7 formed 4-OH-phenyl-mazapertine (M1, 18%) and 4-OH-piperidyl (M2, 14%)-mazapertine, carboxybenzoylpiperidine (M8, 10%) and its glucuronide (M9, 14%) as four major metabolites. Six moderate and minor metabolites (M3-M7 & M10; each < or =10%) formed via a combination of pathways 1-6. Mazapertine is extensively metabolized in humans.

Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites. Publishing Authors By Initials

WN Wu,LA McKown,AB Reitz,WN Wu,LA McKown,AB Reitz,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE: 2007 Jul-Sep

Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of drug metabolism and pharmacoki

VOLUME: 32

Page Numbers: 171-6

Journal Abbreviation:

ISSN: 0398-7639

DAY: 7

MONTH: 12

YEAR: 2007

Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7608491

Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites.

AFFILIATION: Johnson & Johnson Pharmaceutical Research & Development, LLC, Spring House, PA 19477, USA.

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Drug Metab Pharmacokinet

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites Related Publications

• "One-and-half ventricle" cardiac transplantation for complex congenital heart disease.
• 8-(Heteroaryl)phenalkyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-ones as opioid receptor modulators.
• A cross-sectional study of bone turnover markers in healthy premenopausal women.
• A review of present methods in the early diagnosis of bronchogenic carcinoma.
• An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.
• Antibiotic effects of circulin against certain gram-negative plant pathogens.
• Basic principles governing animals and their treatment.
• Can the ice-water test predict the outcome of intradetrusor injections of botulinum toxin in patients with neurogenic bladder dysfunction?
• Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
• Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
• Competitive exclusion of a worldwide invasive pest by a native. Quantifying competition between two phytophagous insects on two host plant species.
• Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa.
• Ecology. Invasion of the whiteflies.
• Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
• Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi].
• Fractional polynomials in a new metastatic renal carcinoma continuous prognostic index involving histology, laboratory, and clinical predictors.
• Heart lung transplantation.
• Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites.
• Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
• Peripheral Blood Neutrophils as Independent Immunologic Predictor of Response and Long-Term Survival upon Immunotherapy in Metastatic Renal-Cell Carcinoma.
• Pneumatic paracorporeal ventricular assist device in infants and children: initial Stanford experience.
• Safety assessment of dairy microorganisms: Bacterial taxonomy.
• The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease.
• Twenty-year survivors of heart transplantation at stanford university.